QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.51 (-1.16%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
OTCMKTS:RNUGF

ReNeuron Group (RNUGF) Stock Price, News & Analysis

$0.0011
0.00 (0.00%)
(As of 04/18/2024 ET)
Today's Range
$0.0011
$0.0011
50-Day Range
$0.00
$0.05
52-Week Range
$0.00
$0.05
Volume
N/A
Average Volume
126 shs
Market Capitalization
$62,887.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RNUGF stock logo

About ReNeuron Group Stock (OTCMKTS:RNUGF)

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

RNUGF Stock Price History

RNUGF Stock News Headlines

Rugvista Group AB (RUG)
ReNeuron appoints new scientific advisory board
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
ReNeuron says positive iPSC data presented at conference
ReNeuron Group says positive iPSC data presented at conference
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
ReNeuron Group Names John Hawkins CFO - Quick Facts
See More Headlines
Receive RNUGF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:RNUGF
Previous Symbol
NASDAQ:RNUGF
CIK
N/A
Fax
N/A
Employees
26
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$640,000.00
Book Value
$0.11 per share

Miscellaneous

Free Float
N/A
Market Cap
$62,887.00
Optionable
Not Optionable
Beta
0.52
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Iain Gladstone Ross B.Sc. (Age 70)
    BSc (Hons), C.DIR, CH.D, Executive Chairman
    Comp: $542.99k
  • Mr. John Michael Hawkins A.C.A. (Age 58)
    Company Secretary, CFO & Director
    Comp: $243.6k
  • Dr. John David Sinden B.A. (Age 73)
    BA, M.A., MA, Ph.D., Co-Founder
    Comp: $130.06k
  • Ms. Suzanne Hancock
    Chief Operations Officer
  • Dr. Randolph Corteling Ph.D.
    Chief Scientific Officer
  • Mr. Simon Dew
    Chief Business Officer

RNUGF Stock Analysis - Frequently Asked Questions

How have RNUGF shares performed in 2024?

ReNeuron Group's stock was trading at $0.0515 at the beginning of 2024. Since then, RNUGF stock has decreased by 97.9% and is now trading at $0.0011.
View the best growth stocks for 2024 here
.

How do I buy shares of ReNeuron Group?

Shares of RNUGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:RNUGF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners